Studies show that GLP-1's may improve the mental wellbeing of patients with diabetes and/or obesity. Patients using a GLP-1 might see improvements in the quality of life both physically and mentally. It is suspected that GLP-1's may have an impact on patients with...
The FDA recently granted approval to Novo Nordisk’s Wegovy (semaglutide) for the treatment of noncirrhotic metabolic dysfunction–associated steatohepatitis (MASH). Approximately 6% of U.S. adults (14.9 million people) have MASH (formerly known as nonalcoholic steatohepatitis [NASH]), and its prevalence is growing...
Mercer, a consulting firm, recently published the results of their new survey. Employers with at least 500 employees were surveyed and according to the results, 51% said they plan to increase cost-sharing in 2026, including raising ...
On June 18, 2025, the FDA approved Gilead’s Yeztugo (lenacapavir) for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired human immunodeficiency virus type 1 (HIV-1). Yeztugo is the first FDA-approved, twice-yearly, subcutaneous PrEP option for HIV prevention. Gilead has announced that the list price for Yeztugo will be...
The glucagon-like peptide-1 (GLP-1) drug class is expected to continue to expand in both the indications the class treats as well as the number of GLP-1 medications brought to market.
Several GLP-1 medications could receive FDA approval to expand the indications they are approved for by the end of 2025, this includes ...
